Charles River LaboratoriesRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Charles River Laboratories (CRL) reported revenue of $1.00B in Q2 2026, with Discovery and Safety Assessment its largest revenue segment at 60%.
Charles River LaboratoriesProvides research models and drug-development services spanning discovery and safety assessment, research-model supply, and manufacturing-support testing for biopharma and academic clients.
Charles River Laboratories (CRL) is a Life Sciences Tools & Services company. Provides research models and drug-development services spanning discovery and safety assessment, research-model supply, and manufacturing-support testing for biopharma and academic clients. It was founded in 1947, is headquartered in Wilmington, Massachusetts and employs about 19,700 people.
As of 2026-Q2, Charles River Laboratories's revenue breaks down across Discovery and Safety Assessment (60%), Research Models and Services (21%), Manufacturing Support (19%). See the revenue-by-segment chart for the full mix.
Track Charles River Laboratories's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Charles River Laboratories in the Healthcare sector, alongside Revvity (RVTY), Agilent Technologies (A), Danaher Corporation (DHR), IQVIA (IQV), Mettler Toledo (MTD) and Bio-Techne (TECH).
If you are researching Charles River Laboratories, also look at Revvity (RVTY), Agilent Technologies (A) and Danaher Corporation (DHR). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026